Harrison H,Farnie G,Howell SJ,et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor [J]. Cancer Res,2010,70(2)∶709-718
[2]
Keita Shibuya MO,Shuhei Suzuki,Manabu Seino,et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells [J]. Oncotarget,2014,6()∶11
[3]
Lee SH,Oh SY,Do SI,et al. SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma [J]. Br J Cancer,2014,111(11)∶2122-2130
[4]
Marion Gilormini,Céline Malesys,Emma Armandy,et al. Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC [J]. Oncotarget,2016,7(13)∶16731-16744
[5]
Silvia Santamaria,Marisa Delgado,Leonor Kremer,et al. Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible [J]. Front Immuol, 2017, 8∶1509
[6]
Zhang Q,Shi S,Yen Y,et al. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy [J]. Cancer Lett,2010,289(10)∶151-160
[7]
Hadnagy A,Gaboury L,Beaulieu R,et al. SP analysis may be used to identify cancer stem cell populations [J]. Exp Cell Res,2006,312(19)∶3701-3710
[8]
Loebinger MR,Giangreco A,Groot KR,et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade [J]. Br J Cancer,2008,98(2)∶380-387
[9]
Zhang ZC,Jacques E. N？r. The biology of head and neck cancer stem cells [J]. Oral Oncol,2012,48(1)∶1-9
[10]
Clark J,Li W,Smith G,et al. Outcome of treatment for advanced cervical metastatic squamous cell carcinoma [J]. Head Neck,2005,27(2)∶87-94
[11]
Ghuwalewala S,Ghatak D,Das P,et al. CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma [J]. Stem Cell Res,2016,16(2)∶405-417
[12]
Furth J,Kahn MC. The transmission of leukemia in mice with a single cell [J]. Am J Cancer,1937
[13]
Lapidot T,Sirard C,Vormoor J,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice [J]. Nature,1994,367(4)∶645-648
[14]
Koichi Shimano MS,Atsuhito Okaya,Junichi Kitanaka,et al. Hepatic Oval Cells Have the Side Population Phenotype Defined by Expression of ATP-Binding Cassette Transporter ABCG2/BCRP1 [J]. American Journal of Pathology,2003,163(1)∶3-9
[15]
Bragado P,Estrada Y,Sosa MS,et al. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties [J]. PLoS One,2012,7(1)∶e29974
[16]
Simple M,Suresh A,Das D,et al. Cancer stem cells and field cancerization of oral squamous cell carcinoma [J]. Oral Oncol,2015,51(7)∶643-651
[17]
Lee SW,Jeong HK,Lee JY,et al. Hypoxic priming of mESCs accelerates vascular-lineage differentiation through HIF1-mediated inverse regulation of Oct4 and VEGF [J]. EMBO Mol Med,2012,4(9)∶924-938
[18]
Furuta E,Okuda H,Kobayashi A,et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications [J]. Biochim Biophys Acta,2010,1805(2)∶141-152
[19]
Zhang W,Chen H,Lv S,et al. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma [J]. Mol Neurobiol,2016,53(2)∶2354-2360
[20]
Clevers H. The cancer stem cell: premises, promises and challenges [J]. Nat Med,2011,17(3)∶313-319
[21]
Lee SH,Koo BS,Kim JM,et al. Wnt/beta-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4 [J]. J Pathol,2014,234(1)∶99-107
[22]
Tannishtha Reya SJM,Michael F. Clarke & Irving L,Weissman. Stem cells, cancer, and cancer stem cells [J]. Nature,2001,414(6859)∶105-111
[23]
RitchieK. E NE. Perivascular stem cell niche in head and neck cancer [J]. Cancer Lett,2013,338(1)∶41-46
[24]
Al Hajj M,Wicha MS,Benito Hernandez A,et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci U S A,2003,100(7)∶3983-3988
[25]
Prince ME,Sivanandan R,Kaczorowski A,et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma [J]. Proc Natl Acad Sci U S A,2007,104(3)∶973-978
[26]
Mery B,Guy JB,Espenel S,et al. Targeting head and neck tumoral stem cells: From biological aspects to therapeutic perspectives [J]. World J Stem Cells,2016,8(1)∶13-21
[27]
Sudha Krishnamurthy ZD,Dmitry Vodopyanov,Atsushi Imai,et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells [J]. Cancer Res,2010,70(23)∶15
[28]
McCord AM,Jamal M,Williams ES,et al. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines [J]. Clin Cancer Res,2009,15(16)∶5145-5153
[29]
Yuta Wakamatsu NS,Htoo Zarni Oo,Yutaka Naito,et al. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer [J]. Pathology International,2012,62(2)∶8
[30]
Sophos NA,Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update [J]. Chemico-Biological Interactions,2003,143-144∶5-22
[31]
Chen YC,Chen YW,Hsu HS,et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer [J]. Biochem Biophys Res Commun,2009,385(3)∶307-313
[32]
Sun Q,Zhong Y,Wu F,et al. Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice [J]. BMC Med,2012,10∶172
[33]
Spradling SJMaAC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life [J]. Cell,2008,132(4)∶27
[34]
Calabrese C,Poppleton H,Kocak M,et al. A perivascular niche for brain tumor stem cells [J]. Cancer Cell,2007,11(1)∶69-82
[35]
Albini A,Bruno A,Gallo C,et al. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity [J]. Connect Tissue Res,2015,56(5)∶414-425
[36]
Joshua B,Kaplan MJ,Doweck I,et al. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness [J]. Head Neck,2012,34(1)∶42-49
[37]
Jordi Codony-Servat,Rafael Rosell. Cancer stem cells and immunoresistance: clinical implications and solutions [J]. Transl Lung Cancer Res,2015,4(6)∶689-703
[38]
Lang R, Patel D, Morris JJ, et al. Shaping gene expression in activated and resting primary macrophages by IL-10 [J]. J Immunol, 2002, 169∶2253-63
[39]
Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity [J]. Nat Med,2005,11∶1314-21
[40]
Moreb JS, Ucar-Bilyeu DA, Khan A. Use of retinoic acid/aldehyde dehy-drogenase pathway as potential targeted therapy against cancer stem cells [J]. Cancer Chemother Pharmacol,2017,79(2)∶295-301
[41]
Cimmino L, Dolgalev I, Wang Y, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression [J]. Cell,2017,170∶1079-95
[42]
Argiris A,Karamouzis MV,Raben D,et al. Head and neck cancer [J]. The Lancet,2008,371(9625)∶1695-1709
[43]
Prince ME,Zhou L,Moyer JS,et al. Evaluation of the immunogenicity of ALDH(high) human head and neck squamous cell carcinoma cancer stem cells in vitro [J]. Oral Oncol,2016,59∶30-42
[44]
de Jong MC,Pramana J,van der Wal JE,et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer [J]. Clin Cancer Res,2010,16(21)∶5329-5338
[45]
Christophe Ginestier,Min Hee Hur,Emmanuelle Charafe-Jauffret,et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J]. Cell Stem Cell,2007,1(5)∶555-567
[46]
Sullivan JP,Spinola M,Dodge M,et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling [J]. Cancer Res,2010,70(23)∶9937-9948
[47]
Jin L,Hope KJ,Zhai Q,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells [J]. Nat Med,2006,12(10)∶1167-1174
